Scott A. Gangloff - Apr 29, 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Technology Officer
Signature
/s/ Jonathan Young, Attorney-in-fact
Stock symbol
AKRO
Transactions as of
Apr 29, 2024
Transactions value $
$0
Form type
4
Date filed
5/1/2024, 07:36 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +225K $0.00 225K Apr 29, 2024 Common Stock 225K $19.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five (25) percent of the shares subject to this option shall vest and become exercisable on April 29, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.